Estrella Immunopharma, Inc. Warrant 2021-15.10.27 on Estrella ImmunopharmaEstrella Immunopharma, Inc. Warrant 2021-15.10.27 on Estrella ImmunopharmaEstrella Immunopharma, Inc. Warrant 2021-15.10.27 on Estrella Immunopharma

Estrella Immunopharma, Inc. Warrant 2021-15.10.27 on Estrella Immunopharma

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪43.72 M‬USD
−0.3699USD
‪−8.85 M‬USD
0.00USD
‪41.14 M‬
Beta (1Y)
1.80

About Estrella Immunopharma, Inc.


CEO
Cheng Liu
Headquarters
Emeryville
Founded
2022
Identifiers
3
ISIN US2975841121
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Displays a symbol's price movements over previous years to identify recurring trends.